{"protocolSection":{"identificationModule":{"nctId":"NCT00318136","orgStudyIdInfo":{"id":"AVF3744g"},"organization":{"fullName":"Genentech, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)","officialTitle":"A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2010-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-09"},"primaryCompletionDateStruct":{"date":"2009-07","type":"ACTUAL"},"completionDateStruct":{"date":"2009-07","type":"ACTUAL"},"studyFirstSubmitDate":"2006-04-24","studyFirstSubmitQcDate":"2006-04-24","studyFirstPostDateStruct":{"date":"2006-04-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-03-19","resultsFirstSubmitQcDate":"2010-03-19","resultsFirstPostDateStruct":{"date":"2010-04-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-05-05","lastUpdatePostDateStruct":{"date":"2010-05-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Clinical Trials Posting Group","oldOrganization":"Genentech, Inc."},"leadSponsor":{"name":"Genentech, Inc.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is an open-label, single-arm, multicenter pilot study to evaluate the safety and efficacy of carboplatin/paclitaxel+bevacizumab in subjects with locally advanced (Stage IIIb with pleural effusion/pericardial effusion), Stage IV, or recurrent squamous Non-Small Cell Lung Cancer (NSCLC) who have not received prior systemic therapy for metastatic disease."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["BRIDGE","NSCLC","Lung Cancer","Avastin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":47,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treated with Bevacizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Bevacizumab","Drug: Carboplatin","Drug: Paclitaxel"]}],"interventions":[{"type":"DRUG","name":"Bevacizumab","description":"15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3","armGroupLabels":["Treated with Bevacizumab"]},{"type":"DRUG","name":"Carboplatin","description":"Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles","armGroupLabels":["Treated with Bevacizumab"]},{"type":"DRUG","name":"Paclitaxel","description":"Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles","armGroupLabels":["Treated with Bevacizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Grade ≥3 Pulmonary Hemorrhage Adverse Events","description":"To estimate the rate of National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE), Version 3.0, Grade ≥3 pulmonary hemorrhage adverse events. Per NCI CTCAE v.3: \"Grade 3 = Transfusion, interventional radiology, endoscopic, or operative intervention indicated; radiation therapy (i.e., hemostasis of bleeding site); Grade 4 = Life-threatening consequences; major urgent intervention indicated; Grade 5 = Death.\"","timeFrame":"First bevacizumab administration until 60 days after discontinuation of bevacizumab or death"}],"secondaryOutcomes":[{"measure":"Selected Adverse Events","description":"Selected treatment-emergent adverse events for any grade of pulmonary hemorrhage, any grade of non-pulmonary hemorrhage, any grade of gastrointestinal perforation, Grade ≥ 2 arterial thromboembolic events, Grade ≥ 2 left ventricular systolic dysfunction, Grade ≥ 3 proteinuria, and Grade ≥ 3 hypertension. Refer to NCI CTCAE v.3 for grading definitions.\n\nSerious adverse events (SAEs) occurring in any of the above categories are included. See the Serious Adverse Events section below for full SAE reporting.","timeFrame":"First bevacizumab administration until 60 days after discontinuation of bevacizumab or death"},{"measure":"Adverse Events That Led to Discontinuation of Bevacizumab","description":"Any treatment-emergent adverse event leading to study treatment discontinuation","timeFrame":"First bevacizumab administration until 60 days after discontinuation of bevacizumab or death"},{"measure":"Progression-free Survival","description":"Progression-free survival (PFS) was defined as the time from enrollment to the time of documented disease progression or death from any cause, whichever occurred earlier. PFS was determined for only those patients that received bevacizumab.\n\nSummary of PFS (median) was estimated from Kaplan-Meier curve. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley.","timeFrame":"Length of study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed Informed Consent Form(s)\n* At least 18 years of age\n* Advanced histologically or cytologically confirmed predominant squamous NSCLC\n* Subjects with treated brain metastases are eligible if there is no evidence of progression or hemorrhage after treatment of the brain metastasis/metastases\n* Prior treatment for CNS disease as deemed appropriate by the treating physician\n* ECOG performance status 0, 1, or 2\n* Measurable or evaluable disease\n* Use of an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study (for women of childbearing potential and sexually active men)\n\nExclusion Criteria:\n\n* Prior chemotherapy for metastatic disease\n* Adjuvant chemotherapy or prior combined modality therapy (chemotherapy plus radiotherapy) if \\< 6 months has elapsed from completion of treatment to Day 1, Cycle 1\n* Extrathoracic metastases as the only sites of disease\n* Active malignancy other than lung cancer\n* Current, recent, or planned participation in another experimental drug study\n* Untreated brain metastases\n* Presence of intrathoracic lesion(s) with any cavitation\n* Gross hemoptysis within 3 months prior to Day 1\n* In the opinion of the investigator or local radiologist, evidence of tumor that is extending into the lumen of a major blood vessel\n* Inadequately controlled hypertension\n* Unstable angina or NYHA Grade II or greater CHF\n* Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1\n* Myocardial infarction within 6 months prior to Day 1, Cycle 1\n* Stroke within 6 months prior to Day 1, Cycle 1\n* Active symptomatic peripheral vascular disease within 6 months prior to Day 1, Cycle 1\n* History of significant vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Current, ongoing treatment with full-dose warfarin or its equivalent\n* Current or recent use of aspirin (\\>325 mg/day)\n* Known hypersensitivity to any components of bevacizumab\n* Serious, non-healing wound, ulcer, or bone fracture\n* UPC ratio ≥ 1.0\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, Cycle 1, or anticipation of need for major surgical procedure during the course of the study\n* Pregnancy or lactation\n* Inadequate organ function\n* Any other medical conditions (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a subject's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Leonardo Faoro, M.D.","affiliation":"Genentech, Inc.","role":"STUDY_DIRECTOR"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Treated With Bevacizumab","description":"Chemotherapy (carboplatin + paclitaxel) in combination with bevacizumab in intervals of chemotherapy alone (Cycles 1 and 2), chemotherapy + bevacizumab (Cycles 3-6), and bevacizumab alone (Cycles 7 and beyond)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"47"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"45"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treated With Bevacizumab","description":"Chemotherapy (carboplatin + paclitaxel) in combination with bevacizumab in intervals of chemotherapy alone (Cycles 1 and 2), chemotherapy + bevacizumab (Cycles 3-6), and bevacizumab alone (Cycles 7 and beyond)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"}]}],"measures":[{"title":"Age Continuous","description":"Of the 47 enrolled subjects, 31 met the protocol-specified criteria and received bevacizumab.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.0","spread":"7.9"}]}]}]},{"title":"Sex: Female, Male","description":"Of the 47 enrolled subjects, 31 met the protocol-specified criteria and received bevacizumab.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"21"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Grade ≥3 Pulmonary Hemorrhage Adverse Events","description":"To estimate the rate of National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE), Version 3.0, Grade ≥3 pulmonary hemorrhage adverse events. Per NCI CTCAE v.3: \"Grade 3 = Transfusion, interventional radiology, endoscopic, or operative intervention indicated; radiation therapy (i.e., hemostasis of bleeding site); Grade 4 = Life-threatening consequences; major urgent intervention indicated; Grade 5 = Death.\"","populationDescription":"Safety-evaluable patients","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients","timeFrame":"First bevacizumab administration until 60 days after discontinuation of bevacizumab or death","groups":[{"id":"OG000","title":"Treated With Bevacizumab","description":"Chemotherapy (carboplatin + paclitaxel) in combination with bevacizumab in intervals of chemotherapy alone (Cycles 1 and 2), chemotherapy + bevacizumab (Cycles 3-6), and bevacizumab alone (Cycles 7 and beyond)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Blyth-Still-Casella","paramType":"Percentage of patients","paramValue":"3.2","ciPctValue":"90","ciLowerLimit":"0.3","ciUpperLimit":"13.5"}]},{"type":"SECONDARY","title":"Selected Adverse Events","description":"Selected treatment-emergent adverse events for any grade of pulmonary hemorrhage, any grade of non-pulmonary hemorrhage, any grade of gastrointestinal perforation, Grade ≥ 2 arterial thromboembolic events, Grade ≥ 2 left ventricular systolic dysfunction, Grade ≥ 3 proteinuria, and Grade ≥ 3 hypertension. Refer to NCI CTCAE v.3 for grading definitions.\n\nSerious adverse events (SAEs) occurring in any of the above categories are included. See the Serious Adverse Events section below for full SAE reporting.","populationDescription":"Safety-evaluable patients","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Patients","timeFrame":"First bevacizumab administration until 60 days after discontinuation of bevacizumab or death","groups":[{"id":"OG000","title":"Treated With Bevacizumab","description":"Chemotherapy (carboplatin + paclitaxel) in combination with bevacizumab in intervals of chemotherapy alone (Cycles 1 and 2), chemotherapy + bevacizumab (Cycles 3-6), and bevacizumab alone (Cycles 7 and beyond)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"title":"Any grade of pulmonary hemorrhage","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Any grade of non-pulmonary hemorrhage","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any grade of gastrointestinal perforation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Grade ≥ 2 arterial thromboembolic events","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Grade ≥ 2 left ventricular systolic dysfunction","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Grade ≥ 3 proteinuria","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Grade ≥ 3 hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}]},{"type":"SECONDARY","title":"Adverse Events That Led to Discontinuation of Bevacizumab","description":"Any treatment-emergent adverse event leading to study treatment discontinuation","populationDescription":"Safety-evaluable patients","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Patients","timeFrame":"First bevacizumab administration until 60 days after discontinuation of bevacizumab or death","groups":[{"id":"OG000","title":"Treated With Bevacizumab","description":"Chemotherapy (carboplatin + paclitaxel) in combination with bevacizumab in intervals of chemotherapy alone (Cycles 1 and 2), chemotherapy + bevacizumab (Cycles 3-6), and bevacizumab alone (Cycles 7 and beyond)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"title":"Cerebral Infarction","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Cerebral Ischemia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Neuropathy Peripheral","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Deep Vein Thrombosis","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Pulmonary Embolism","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Cardiac Failure Congestive","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Proteinuria","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Progression-free survival (PFS) was defined as the time from enrollment to the time of documented disease progression or death from any cause, whichever occurred earlier. PFS was determined for only those patients that received bevacizumab.\n\nSummary of PFS (median) was estimated from Kaplan-Meier curve. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley.","populationDescription":"Enrolled patients","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Length of study","groups":[{"id":"OG000","title":"Treated With Bevacizumab","description":"Chemotherapy (carboplatin + paclitaxel) in combination with bevacizumab in intervals of chemotherapy alone (Cycles 1 and 2), chemotherapy + bevacizumab (Cycles 3-6), and bevacizumab alone (Cycles 7 and beyond)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","lowerLimit":"5.32","upperLimit":"7.62"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"Treated With Bevacizumab","description":"Chemotherapy (carboplatin + paclitaxel) in combination with bevacizumab in intervals of chemotherapy alone (Cycles 1 and 2), chemotherapy + bevacizumab (Cycles 3-6), and bevacizumab alone (Cycles 7 and beyond).","seriousNumAffected":18,"seriousNumAtRisk":31,"otherNumAffected":12,"otherNumAtRisk":31}],"seriousEvents":[{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Pulmonary Hemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Bronchitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Infection","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Pneumonia","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Basal Ganglia Infarction","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Cerebral Infarction","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Cerebral Ischemia","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31}]},{"term":"Hypotension","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Atrial Flutter","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Cardiac Failure Congestive","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Small Intestinal Obstruction","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Pain","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Hip Fracture","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Confusional State","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]}],"otherEvents":[{"term":"Hypertension","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":31}]},{"term":"Asthenia","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Chest Pain","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Chills","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Fatigue","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Pyrexia","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31}]},{"term":"Neuropathy Peripheral","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31}]},{"term":"Sinusitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Genentech, Inc.","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["United States"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}